Scleroderma Lung Study II—clarity or obfuscation?

The Lancet Respiratory Medicine

Volumn 4, Issue 9, 2016, Pages 678-679

  Denton, Christopher P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; PLACEBO;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DIFFUSING CAPACITY OF THE LUNG FOR CARBON MONOXIDE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA SCORE; EVIDENCE BASED PRACTICE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; MODIFIED RODNAN SKIN SCORE; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RATING SCALE; RESPIRATORY TRACT PARAMETERS; SCLERODERMA; SKINFOLD THICKNESS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; SYSTEMIC SCLEROSIS;

HUMANS; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC;

EID: 84989835495     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30191-6     Document Type: Note

References (10)

1. 1 Tyndall, AJ, Bannert, B, Vonk, M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69 (2010), 1809–1815.
2. 2 Galiè, N, Barberà, JA, Frost, AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 373 (2015), 834–844.
3. 3 Tashkin, DP, Roth, MD, Clements, PJ, et al., for the Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med, 2016 published online July 25. http://dx.doi.org/10.1016/S2213-2600(16)30152-7.
4. 4 Tashkin, DP, Elashoff, R, Clements, PJ, et al., Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176 (2007), 1026–1034.
5. 5 Tashkin, DP, Elashoff, R, Clements, PJ, et al., Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354 (2006), 2655–2666.
6. 6 Nihtyanova, SI, Brough, GM, Black, CM, Denton, CP, Mycophenolate mofetil in diffuse cutaneous systemic sclerosis—a retrospective analysis. Rheumatology (Oxford) 46 (2007), 442–445.
7. 7 Mendoza, FA, Nagle, SJ, Lee, JB, Jimenez, SA, A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 39 (2012), 1241–1247.
8. 8 Nihtyanova, SI, Schreiber, BE, Ong, VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 66 (2014), 1625–1635.
9. 9 van Laar, JM, Farge, D, Sont, JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311 (2014), 2490–2498.
10. 10 Hoyles, RK, Ellis, RW, Wellsbury, J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54 (2006), 3962–3970.